Neu H C
Division of Infectious Disease, College of Physicians and Surgeons, Columbia University, New York, New York 10032.
Am J Med. 1989 Dec 29;87(6C):2S-9S.
In the past decade, significant progress has been made in understanding structure-function relationships of the new quinolones, which have a N-1-substituted, 1,4-dihydro-4-oxo-pyridine-3-carboxylic acid moiety as the basic nucleus. Modification of the groups affixed to positions C-6, C-7, and C-8 has made a major change in the antimicrobial activity, pharmacokinetic, and metabolic properties of the quinolones as have changes in the moieties affixed to the N-1 nitrogen. The new quinolones have a carboxyl group at position 3 and a keto group at C-4. The presence of a fluorine atom at C-6 enhances the deoxyribonucleic acid (DNA) gyrase inhibitory activity as well as the ability of the compounds to inhibit staphylococci. Position C-7 has been one of the most modified sites. Addition of a piperazinyl group markedly increased gram-positive activity, primarily antistaphylococcal activity; lowered the minimal inhibitory concentrations against Enterobacteriaceae, Haemophilus spp., and Neisseria spp.; and added activity against Pseudomonas aeruginosa compared with nalidixic acid. Methyl derivatives of the piperazine group or of the pyrroles have longer half-lives than do unsubstituted moieties. At the N-1 position, a cyclopropyl group appears to be most potent with respect to minimal inhibitory concentrations against Enterobacteriaceae and Pseudomonas. Ofloxacin is unique in that it has an oxygen substituted at C-8 with the substituent part of the ring system formed by fusion to the N-1 position. This has produced excellent in vitro activity against gram-positive species comparable with that of ciprofloxacin, excellent activity against the Enterobacteriaceae, and antipseudomonal activity superior to agents with an ethyl substitution at position N-1. The oxazine ring of ofloxacin provides excellent oral absorption with virtually 95 percent bioavailability; this modification also has prevented metabolism and has provided a long half-life of seven to eight hours.
在过去十年中,对于新型喹诺酮类药物结构-功能关系的理解取得了显著进展,这类药物以N-1-取代的1,4-二氢-4-氧代吡啶-3-羧酸部分作为基本核心。连接在C-6、C-7和C-8位上的基团修饰,以及连接在N-1氮原子上的部分基团变化,都使喹诺酮类药物的抗菌活性、药代动力学和代谢特性发生了重大改变。新型喹诺酮类药物在3位有一个羧基,在C-4位有一个酮基。C-6位存在氟原子可增强脱氧核糖核酸(DNA)回旋酶抑制活性以及化合物抑制葡萄球菌的能力。C-7位一直是修饰最多的位点之一。添加哌嗪基团显著增强了革兰氏阳性菌活性,主要是抗葡萄球菌活性;降低了对肠杆菌科、嗜血杆菌属和奈瑟菌属的最低抑菌浓度;与萘啶酸相比,还增加了对铜绿假单胞菌的活性。哌嗪基团或吡咯的甲基衍生物比未取代部分具有更长的半衰期。在N-1位,环丙基对于肠杆菌科和假单胞菌的最低抑菌浓度似乎最为有效。氧氟沙星的独特之处在于它在C-8位被氧取代,取代基部分与N-1位稠合形成环系。这使其对革兰氏阳性菌产生了与环丙沙星相当的出色体外活性,对肠杆菌科有出色活性,并且抗假单胞菌活性优于N-1位为乙基取代的药物。氧氟沙星的恶嗪环具有出色的口服吸收效果,生物利用度几乎达到95%;这种修饰还防止了代谢,并提供了7至8小时的长半衰期。